INTRODUCTION
Daily oral emtricitabine (FTC)/tenofovir (TFV) disoproxil fumarate (TDF)-based preexposure prophylaxis (PrEP) has demonstrated efficacy in preventing HIV transmission and is being scaled up among high-risk populations, including men who have sex with men (MSM).
Randomized trials of PrEP, delivered either daily or on-demand, reported reductions in HIV incidence (between 44-86% in intervention groups) which correlated strongly with objective adherence measures. [1] [2] [3] [4] [5] [6] [7] Moreover, in trials where pharmacologic measures identified low overall PrEP adherence (e.g., FEM-PrEP, VOICE), the efficacy of the intervention was nil. 8, 9 PrEP demonstration projects have shown the effectiveness of PrEP for HIV prevention in more "realworld" settings and, while some participants appear to be more adherent to PrEP when they know the product is effective, not all choose to initiate or adhere during risk periods. 10-13 PrEP delivery programs must now focus on understanding PrEP pill-taking patterns and improving PrEP adherence to maximize its effectiveness among high-risk populations. 7 PrEP adherence monitoring is crucial for accurately interpreting PrEP effectiveness and identifying individuals who may benefit from additional adherence support. However, PrEP delivery projects vary in the adherence metrics employed, despite limitations of each. For example, self-reported adherence is subject to recall or social desirability bias and may considerably over-estimate PrEP use. [14] [15] [16] Electronic monitoring devices, such as Wisepill™ (Wisepill Techologies, Cape Town, South Africa) and medication event monitoring systems (MEMS) overcome some of these biases, but do not measure actual drug ingestion or drug levels in target tissues. 14,17 PrEP drug levels in various biomatrices represent different periods of drug exposure 18, 19 and have shown utility in PrEP studies. Plasma drug concentrations represent a small window of exposure (up to one week prior to sample collection, depending on the assay)
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and could be susceptible to intra-individual variability and "white coat effects", whereby participants take doses just prior to a clinic visit without consistent use, although this issue was not observed in previous PrEP clinical trials. [20] [21] [22] PrEP drug levels in hair samples (which are noninvasive to collect and inexpensive to store) provide data on long-term drug exposure (weeks to months) and have been employed in several PrEP studies.
23-25
Combining and comparing metrics of PrEP adherence (electronic, pharmacologic) will further assess their utility, characterize predictors and patterns of short and long-term PrEP dosing, and inform future PrEP delivery and adherence interventions. An analysis found that the combination of plasma and hair data had a higher ability to discriminate between low, moderate, and high levels of adherence than the use of a single PrEP exposure measure. 26 In our study, we compared Wisepill™ data on PrEP dosing with plasma and hair FTC and TFV concentrations in a sample of 350 HIV-uninfected MSM participating in a PrEP delivery trial in Thailand and the United States (U.S.). This analysis provides a unique contribution to the literature by : 1) longitudinally examining correlations between these PrEP adherence measures across a large number of study visits, over three PrEP dosing strategies, and among two high-risk populations and 2) exploring predictors of both recent and long-term PrEP dosing assessed via plasma and hair drug concentrations, respectively.
METHODS

Study design and participants
The 
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Bangkok, Thailand, and Harlem, New York, U.S., with the main study findings described previously. 27 Although this study also enrolled transgender women (TGW) in Bangkok and
Harlem, and cisgender women in Cape Town, South Africa, as has been reported elsewhere, 27, 28 this particular analysis is restricted to MSM participants to minimize variability in risk factors. 29, 30 Participants were eligible for enrollment if they were HIV-antibody negative, ≥18
years old, literate in English or Thai and able to consent, reported sex with a man in the past six months, and had at least one risk factor for HIV in the six months prior to enrollment, including sex with more than one male partner, history of sexually transmitted infection, transactional sex, or sex without a condom with an HIV-infected partner or a partner of unknown status.
Participants completed a five-week directly-observed-therapy period, and were then randomly assigned to one of three open-label FTC/TDF PrEP dosing regimens: daily (one tablet every day); time-driven (one tablet twice a week, plus a post-sex dose); and event-driven (one tablet both before and after sex). Regimens were assigned in a 1:1:1 ratio for each site, and participants, staff, and investigators were all aware of treatment assignments. After randomization, participants received a one-month supply of PrEP with the Wisepill™ device and counseling about their dosing regimen. 27,28 Follow-up visits occurred every four weeks until week 24 post-randomization, with 30-day PrEP refills provided at each visit.
Data collection
During enrollment and follow-up visits, participants underwent HIV testing and received HIV counseling, adherence support (Next Step Counseling), and PrEP refills. Blood and hair samples were collected at 4, 12, and 24-week visits for retrospective analysis of drug concentrations, which were not reported to participants or used in adherence counseling.
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Participants completed computer-assisted self-interviewing surveys at all visits to collect data on demographics, HIV risk perception, knowledge, attitudes, and beliefs about PrEP, drug and alcohol use, and depression, along with facilitators and barriers to adherence. These questions were developed based on knowledge of the study sites and previous PrEP trials.
Alcohol use was measured using the validated Alcohol Use Disorders Identification Test (AUDIT) scale (range 0 -40), in which a sum score ≥8 indicates heavy alcohol use.
31
Measures of PrEP use
Daily PrEP use was measured using data from Wisepill™ electronic monitoring devices.
Participants were asked to complete weekly in-person or phone interviews with trained staff, who reviewed each recorded device opening and asked the participant to confirm whether the Wisepill™ device opening was reflective of an ingested dose (rather than a curiosity opening, device refill, or pocket dose). Weekly interview data were used to adjust Wisepill™ data by correcting dates and times for doses removed and taken later, doses removed but not taken, and doses taken from a container other than the Wisepill™("Wisepill™-prompted weekly interviews"). Weekly interview data were used as a measure of PrEP use if no Wisepill™ data were available and participants were also asked about dates, times, and types of sex acts during these interviews.
Blood was collected and processed for plasma, and FTC/TFV levels were quantified via liquid chromatographic-tandem mass spectrometric (LC-MS/MS) analysis within the Clinical Pharmacology Analytical Laboratory (Johns Hopkins University, Baltimore, MD). 32 The lower limits of quantification for both FTC and TFV in plasma are 0.31 ng/mL. For hair collection, approximately 50-100 stands of hair were cut as close as possible to the scalp in the occipital region, placed in aluminum foil, and stored at room temperature until shipped to the University 
Statistical analyses
Descriptive statistics summarized sample characteristics. FTC and TFV drug concentrations were log-transformed in all analyses by taking the natural logarithm of the concentration. Pharmacologic measures below the lower limits of quantification were set equal to that limit prior to log-transformation.
Pearson correlation coefficients assessed correlations between Wisepill™ and pharmacologic measures at the three follow-up visits when plasma and hair samples were collected. In the primary correlation analysis, we included Wisepill™ and continuous drug concentration values from participants in all arms together, but we also conducted sensitivity analyses restricting the sample to each arm separately. We compared the total number of device openings from the Wisepill™ data in the prior week to plasma drug concentrations. We compared Wisepill™ data in the prior month to hair drug concentrations. Correlation analyses were restricted to the sample of participants with Wisepill™, plasma, and hair data available at a given time point, and those missing at least one measure were excluded. All analyses were conducted using SAS 9.4 (Cary, North Carolina, USA).
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Ethical statement
Institutional review board (IRB) approvals were obtained locally in Harlem and Bangkok 
RESULTS
Participant characteristics
The acceptability and availability of hair for sampling. However, only a subset of these data were processed for analysis (N=436 samples), due to pre-specified cost restrictions for hair assays.
The primary reason for missing hair samples was insufficient quantity of hair for sample collection, which was more prevalent in Harlem than in Bangkok. Retention rates were high in the cohort, with 88.0% of participants attending the 24-week visit, although retention differed by site (96.6% in Bangkok vs. 78.8% in Harlem). Geometric mean FTC and TFV concentrations were greater among participants in the daily arm than in the full sample and decreased over the duration of follow-up in both the full sample and among participants in the daily arm indicating waning PrEP use over time (Table 2) .
Correlations between measures of PrEP use
Correlation analysis between Wisepill™ data, plasma FTC/TFV concentrations, and hair 
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Factors associated with pharmacologic measures of PrEP use
The analysis of factors associated with hair and plasma drug concentrations included data for 381 hair TFV, 379 hair FTC, 946 plasma TFV, and 946 plasma FTC samples, after excluding those with missing covariate data.
In multivariable models of hair concentrations, participants in the intermittent arms who reported zero sex acts had lower concentrations of log-transformed hair TFV and FTC during follow-up than those in the daily arm who reported zero sex acts (p-value <0.001; Table 3 ) when controlling for other variables in the model. The number of sex acts did not influence hair drug concentrations among participants in the daily arm (the main effect for sexual activity was not statistically significant). However, we observed a statistically significant interaction effect between study arm and number of sex acts. Specifically, as the number of reported sex acts increased, participants in the event-driven arm were estimated to have higher hair TFV and FTC concentrations than those in the daily-or time-driven arms, indicating that those with high numbers of sex acts in the event-driven arm were taking PrEP more often than those reporting the same number of sex acts but in the daily dosing arm (top two panels, Figure 2 ). Participants from Harlem had lower hair TFV and FTC concentrations than those from Bangkok (p-values <0.001). Lower education status was negatively associated with hair FTC and TFV concentrations and heavy alcohol use (AUDIT score ≥8) was associated with higher FTC/TFV concentrations. We found similar directions and magnitudes of association in our model assessing correlations between covariates and hair TFV levels ≥0.023 ng/ml (~4 doses per week) among participants in the daily arm only (Table 4 ) but this analysis had limited power to detect statistically significant associations given the smaller number of included visits (N=127; 29.1%
with TFV levels ≥0.023 ng/ml and 70.9% with TFV levels <0.023 ng/ml).
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In models of plasma concentrations, we similarly found that assignment to the intermittent arms was associated with lower FTC and TFV concentrations than assignment to the daily arm among participants who reported zero sex acts, and participants from Harlem had statistically significantly lower TFV concentrations than those from Bangkok, although the association between site and FTC concentrations ( concentrations, we did not observe statistically significant differences in the association between number of sex acts and plasma drug concentrations across the study arms; plasma concentrations were highest for participants in the daily arm regardless of number of reported sex acts (bottom two panels, Figure 2 ). We also did not find statistically significant effects of education or alcohol use on plasma concentrations.
DISCUSSION
In this cohort of MSM participating in a trial to assess behavioral feasibility of non-daily PrEP dosing shortly before study visits, and guide adherence approaches for consistent PrEP use.
The strengths of this study included the large sample with participants from two distinct geographic regions and the use of multiple measures of PrEP exposure. Overall retention rates were high, which minimized concerns about selection bias and differential attrition, but did differ across the two study sites. Limitations of this study included the lack of a gold-standard PrEP adherence measure, which prevented us from quantifying the magnitude of bias due to "whitecoat effects", "curiosity openings", and "pocket dosing". Although we were able to adjust our
Wisepill™ data based on weekly interview data, the validity of these self-report data was potentially limited due to social desirability and recall bias. While objective benchmarks of adherence have been established for pharmacologic measures in directly observed therapy studies, 6 ,25 it was difficult to apply them to this work given important differences in expected PrEP dosing and definitions of adherence by the three randomized study arms. The HPTN 067 primary manuscript provides additional data on PrEP adherence and coverage of sex events for each dosing arm and further analyses of patterns of adherence around recent sex events and using pharmacologic adherence measures are forthcoming. 27 We were only able to analyze hair samples during 43.6% of 999 attended visits due to budget restrictions. Moreover, our results in this MSM cohort may not be generalizable to women or to all men or MSM and the study only enrolled five TGW which prevented us from being able to examine correlates of PrEP adherence in this group. Finally, due to a low number of HIV seroconversions (only 1 acute HIV infection
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after randomization in a participant from Harlem), we could not examine associations between drug concentrations and HIV acquisition in the sample.
In conclusion, Wisepill™, plasma, and hair data were moderately correlated with one another in this phase II PrEP trial, suggesting that these adherence measures can be combined to better understand PrEP exposure during roll-out. In particular, plasma measures may be useful for examining short-term adherence while hair measures can assess longer-term PrEP adherence 2 Participants were coded as "Other" if they reported being American Native, Alaska Native, Asian American, or other race/ethnicity. 3 AUDIT score ≥8 is indicative of heavy alcohol use. 2 Measured per 10 years 3 AUDIT score ≥8 is indicative of heavy alcohol use. 4 Measured per 10 sex acts 2 Measured per 10 years 3 AUDIT score ≥8 is indicative of heavy alcohol use. 4 Measured per 10 sex acts 2 Participants were coded as "Other" if they reported being American Native, Alaska Native, Asian American, or other race/ethnicity. 3 AUDIT score ≥8 is indicative of heavy alcohol use. Models included all covariates shown here. TFV and FTC concentrations are log-transformed (using a natural logarithm transformation) and all regression coefficients were then back-transformed to determine fold-effects. Statistically significant effects (p-value <0.05) are indicated in bold. 2 Measured per 10 years 3 AUDIT score ≥8 is indicative of heavy alcohol use. 4 Measured per 10 sex acts A C C E P T E D Models included all covariates shown here and were restricted to participants in the daily arm only with available hair concentrations (N=57 participants). TFV concentrations are log-transformed (using a natural logarithm transformation), categorized around the natural log of 0.023 (approximately -3.77 ng/mg) and all regression coefficients were then back-transformed to determine fold-effects. Statistically significant effects (pvalue <0.05) are indicated in bold. 2 Measured per 10 years 3 AUDIT score ≥8 is indicative of heavy alcohol use. 4 Measured per 10 sex acts Figures show the predicted drug concentrations (y-axis) by number of sex acts (per 10 acts, x-axis) and study arm. 95% confidence intervals around predicted values are shown with shading around each solid and dashed line.
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